Dear Duchenne Community, We are writing to provide some additional information to accompany our press release (attached) this week about the status of the rolling New Drug Application at the […]
Significant decreases in key biomarkers of muscle damage.
CureDuchenne Ventures is pleased to share that one of our research investments, Code Bio, has announced that have secured $75 million in additional investments to advance their gene therapy programs […]
BioProcess Insider spoke with Michael Kelly, CureDuchenne’s chief scientific officer, to discuss gaps in the gene therapy space and the strategy the firm is adopting to try and fill them. Source: […]
NEWPORT BEACH, Calif. (September 10, 2019) – Finding the right mobility equipment for Duchenne muscular dystrophy patients can be a time intensive and frustrating process. To help take the guesswork […]
The nonprofit CureDuchenne has chosen veteran advocacy leader Erin Frey to become its first director of Duchenne muscular dystrophy (DMD) advancement efforts. Read the full article HERE.
More than $900,000 will go to support CureDuchenne’s mission to find a cure for Duchenne muscular dystrophy and support patients and families affected by this rare genetic disease, all thanks to […]
Scientists are testing nearly two dozen treatments that might stop the disease. But enrollment in the trials is very restricted, and few children qualify. Lucas was 5 before his parents, […]